Moss, 28 January 2026
Gentian Diagnostics ASA will host an educational webinar focused on NT-proBNP, a
widely used biomarker in the diagnosis and management of heart failure.
The live webinar will take place on 25 February 2026 at 15:00 CET and will
feature presentations by Peder L. Myhre, Professor of Cardiology at the
University of Oslo, and Robert H. Christenson, Professor of Pathology at the
University of Maryland School of Medicine.
The webinar will address current clinical use of NT-proBNP as well as biological
and analytical challenges, including the impact of NT-proBNP glycosylation on
assay performance and clinical interpretation.
The webinar forms part of Gentian's ongoing scientific and educational outreach
related to its NT-proBNP development program. A recording will be made available
following the live event.
The webinar is hosted by Labroots and can be accessed via the following link:
https://www.labroots.com/ms/webinar/glycosylation-nt-probnp-clinicians-laborator
ies
For further information, please contact:
Njaal Kind, CFO
njaal.kind@gentian.no
+47 919 06 525
About Gentian Diagnostics
Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in
vitro diagnostic reagents. Our mission is to innovate diagnostic efficiency for
better treatment decisions. Gentian's expertise and focus lie within
immunoassays, specifically for infections, inflammation, kidney disease and
heart failure. By converting existing and clinically relevant biomarkers to the
most efficient, high-throughput analysers, the company contributes to saving
costs and protecting life. Gentian Diagnostics is headquartered in Moss, Norway,
serving the global human and veterinary diagnostics markets through sales and
representative offices in Sweden, USA, and China. For more information, please
visit www.gentian.com.